As of 6 Nov 2026, Onesource Specialty Pharma is loss-making on a trailing 12-month basis, with a net loss of ₹1.62 Cr, so it has no P/E ratio. The share price is ₹1,599.80, 17% below its 52-week high. Debt is 0.30× equity. It is a small-cap company with a market cap of ₹18,346 Cr, ranked 3rd of 20 Biotechnology companies by market cap; the shares fell 14% over the past year.
- ₹1,581.90
- ₹1,619.10
- ₹1,566.00
- ₹1,581.90
- 2.8 L
Health check
- ReturnsBehind
−13.7% over a year, better than 2 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +232.3% a year over 3 years, but loss-making now.
- ProfitabilityWeak
ROCE 0.3% vs peer median 16.7%.
- Balance sheetStretched
Debt 0.30× equity, interest covered 0.2×, Piotroski 3 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹18,346 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 3.10
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- 0.0%
- Peers 14.3%
- ROCE
- 0.3%
- Peers 16.7%
- Debt to equity
- 0.30
- Debt ₹1,755 Cr
- EPS (TTM)
- −₹0.15
- Face value ₹1
- OPM (TTM)
- 23.5%
- Net margin −0.1%
- Sales growth
- +37.4%
- Latest quarter vs a year ago
- Profit growth
- +448.2%
- Latest quarter vs a year ago
- Price to sales
- 10.88
- EV/EBITDA 59.2
Strengths and risks
Strengths
- Quarterly profit up 448.2% on a year ago.
- Quarterly sales up 37.4% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at 0.0%.
- Interest coverage of only 2.5×.
About Onesource Specialty Pharma
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of…
- Headquarters
- Bengaluru
- Employees
- 1,674
- Sector
- Healthcare
- ISIN
- INE013P01021
- Website
- onesourcecdmo.com
Price range
- Avg volume (3M)
- 4.7 L
- 1-year return
- minus 13.7%
- From 52-week high
- minus 16.6%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 19.4% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.60% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.22% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.14% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| DCALDishman Carbogen Amcis | 156.64 | minus 0.56% | 2,456 | 152.1 | 0.37 | 2.7% | 1.6% | 16.1% | 7.5% | – | 0.00% | minus 47.1% |
| Median of 7 peers | – | −0.56% | 9,607 | 66.0 | 4.68 | 16.7% | 14.3% | 21.4% | 15.3% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 376 | 290 | 428 | 449 | 516 | |
| 269 | 273 | 336 | 326 | 353 | |
| 106 | 17.3 | 91.9 | 123 | 163 | |
| 28.3% | 6.0% | 21.5% | 27.5% | 31.6% | |
| 3 | 4.6 | 2.1 | 3.8 | 1 | |
| 34 | 38.2 | 22.5 | 30.8 | 34.6 | |
| 69.8 | 69.6 | 71.8 | 71.7 | 75.1 | |
| – | −7.1 | 0 | −4.3 | −1.8 | |
| 5.7 | −93 | −0.3 | 20.3 | 52.9 | |
| −82.6% | 4.6% | 1674.3% | −23.2% | −8.7% | |
| 10.5 | −88.7 | 4.6 | 25 | 57.5 | |
| 0.91 | -7.74 | 0.40 | 2.18 | 5.01 |
Profit & loss
- Sales CAGR 3Y
- +232.3%
- ROE
- 0.0%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 38.7 | 172 | 1,445 | 1,422 | |
| – | +344.1% | +740.4% | minus 1.6% | |
| 140 | 233 | 1,084 | 1,148 | |
| −102 | −61.1 | 361 | 274 | |
| −262.9% | −35.6% | 25.0% | 19.2% | |
| −15 | −2.7 | 110 | 34.7 | |
| 40.1 | 85.4 | 154 | 111 | |
| 114 | 95.4 | 274 | 279 | |
| −145 | −121 | −110 | −9.8 | |
| −416 | −366 | −67.1 | −92 | |
| – | – | 74.2% | 19.7% | |
| −800 | −391 | −18 | −73.8 | |
| -69.89 | -34.18 | -1.63 | -6.44 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4 | 4 | 11.4 | 11.5 | |
| 781 | 392 | 5,869 | 5,820 | |
| 864 | 571 | 942 | 1,504 | |
| 359 | 342 | 727 | 875 | |
| 2,009 | 1,309 | 7,550 | 8,210 | |
| 1,369 | 744 | 1,004 | 1,450 | |
| 203 | 61.1 | 107 | 524 | |
| – | 3.8 | 6.9 | 10.2 | |
| 9.5 | 22.3 | 211 | 47.5 | |
| 427 | 478 | 6,221 | 6,179 | |
| 2,009 | 1,309 | 7,550 | 8,210 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −163 | −107 | −67.9 | 8.5 | |
| −67.8 | 511 | −201 | −495 | |
| 118 | −391 | 412 | 359 | |
| −112 | 12.8 | 143 | −127 | |
| −44 | −63.8 | −128 | −569 | |
| −207 | −171 | −196 | −561 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 33.3% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.